Int. J. Curr. Res. Med. Sci. (2024). 10(4): 46-53

International Journal of Current Research in Medical Sciences

ISSN: 2454-5716

(A Peer Reviewed, Indexed and Open Access Journal)

www.ijcrims.com

Review Article

Volume 10, Issue 4 -2024

DOI: http://dx.doi.org/10.22192/ijcrms.2024.10.04.005

Sickle Cell Anemia and Pulmonary Complications: Academic Perspectives and Therapeutic Strategies

[*]Emmanuel Ifeanyi Obeagu[1] and Muhammad Tukur[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]Department of Science Education, Faculty of Education, Kampala International University, Uganda.

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle Cell Anemia (SCA) is a hereditary hemoglobinopathy characterized by abnormal hemoglobin production, resulting in the formation of sickle-shaped red blood cells. While traditionally associated with circulatory complications, SCA increasingly manifests with a spectrum of pulmonary complications, including acute chest syndrome (ACS), pulmonary hypertension (PH), asthma, obstructive sleep apnea (OSA), and restrictive lung disease. This review provides an overview of recent academic perspectives on the interplay between SCA and pulmonary complications, highlighting key research advancements and therapeutic strategies aimed at managing these complex respiratory manifestations.Recent academic research has deepened our understanding of the pathophysiological mechanisms underlying pulmonary complications in SCA. Studies have elucidated the role of chronic hemolysis, endothelial dysfunction, and vascular remodeling in the development of pulmonary hypertension, a major contributor to morbidity and mortality in SCA patients. Additionally, genome-wide association studies have identified genetic modifiers of SCA severity, offering insights into potential therapeutic targets and personalized medicine approaches. These advancements underscore the importance of a multidisciplinary approach to SCA management, integrating pharmacological interventions, supportive care, and targeted therapies to optimize respiratory health and improve patient outcomes.

Keywords: Sickle Cell Anemia, Pulmonary Complications, Academic Research, Therapeutic Strategies, Respiratory Health, Hemoglobinopathies, Treatment Modalities

Introduction

Sickle Cell Anemia (SCA) stands as a hallmark among hemoglobinopathies, profoundly impacting millions worldwide. This hereditary disorder arises from a single nucleotide mutation in the β-globin gene, leading to the production of abnormal hemoglobin known as hemoglobin S (HbS). The consequences of this mutation cascade into a myriad of clinical manifestations, prominently characterized by the sickling of red blood cells under conditions of hypoxia or stress.

Traditionally viewed through the lens of its vascular complications, SCA has increasingly unveiled its intricate association with pulmonary manifestations, drawing attention to the intricate interplay between hematology and respiratory physiology.[1-4]Pulmonary complications in SCA represent a complex and multifaceted landscape, encompassing acute and chronic conditions that significantly impact morbidity and mortality. Among these, acute chest syndrome (ACS) stands as a sentinel event, marked by fever, chest pain, and pulmonary infiltrates, often necessitating urgent intervention. The etiology of ACS involves a constellation of factors, including vaso-occlusion, infection, and inflammation, highlighting the intricate interplay between the underlying hematologic abnormalities and pulmonary pathophysiology. Moreover, pulmonary hypertension (PH) emerges as a formidable adversary in the clinical course of SCA, heralding a cascade of vascular remodeling, right heart strain, and ultimately, organ failure.[5-8] The intersection of SCA and pulmonary complications underscores the imperative for a comprehensive understanding of the underlying pathophysiological mechanisms and therapeutic strategies. Recent strides in academic research have illuminated the intricate molecular pathways governing the development and progression of pulmonary manifestations in SCA. Chronic hemolysis emerges as a pivotal driver, fueling endothelial dysfunction, oxidative stress, and dysregulated vasomotor tone within the pulmonary vasculature. Furthermore, genetic modifiers of SCA severity have come to the fore, offering tantalizing insights into personalized medicine approaches and targeted therapeutic interventions.[91-3] The management of pulmonary complications in SCA necessitates a multidisciplinary framework, encompassing pharmacological, supportive, and interventional modalities. Hydroxyurea, a stalwart in SCA therapy, exerts its pleiotropic effects by augmenting fetal hemoglobin levels, reducing vaso-occlusive events, and mitigating pulmonary hypertension. Transfusion therapy, particularly exchange transfusion, emerges as a cornerstone in the management of ACS and stroke prevention, underscoring the pivotal role of erythrocyte transfusion in ameliorating hypoxemia and reversing pulmonary vascular occlusion. Additionally, pulmonary vasodilators, such as prostacyclin analogs and phosphodiesterase-5 inhibitors, offer promise in attenuating pulmonary hypertension and improving exercise capacity, albeit with nuanced considerations regarding their long-term efficacy and safety profiles.[14-17]

Despite notable advancements, a litany of challenges persists in the realm of SCA-related pulmonary complications, encompassing barriers to healthcare access, healthcare disparities, and the paucity of targeted therapeutic agents. Disparities in healthcare access compound the burden of disease, disproportionately affecting marginalized communities and underserved populations. Moreover, the evolving landscape of therapeutic interventions underscores the imperative for robust clinical trials and translational research efforts to bridge the gap between bench and bedside. In light of these challenges, future research endeavors should prioritize elucidating the genetic determinants of SCA-related pulmonary complications, refining existing therapeutic modalities, and fostering collaborative efforts to address healthcare disparities.[18] Comprehensive care models, incorporating telemedicine, community outreach initiatives, and patient education, stand poised to ameliorate disparities in healthcare access and enhance patient outcomes. By harnessing the collective expertise of the scientific community and fostering interdisciplinary collaboration, we can surmount the challenges posed by SCA-related pulmonary complications and forge a path towards optimal respiratory health and improved quality of life for individuals living with this complex hematologic disorder.

Pulmonary Complications in Sickle Cell Anemia

Pulmonary complications in sickle cell anemia (SCA) represent a significant clinical challenge, contributing to morbidity and mortality in affected individuals.[19] These complications encompass a diverse spectrum of acute and chronic conditions that affect the respiratory system, ranging from acute chest syndrome (ACS) to pulmonary hypertension (PH), and

including asthma, obstructive sleep apnea (OSA), and restrictive lung disease. Acute chest syndrome (ACS) is one of the most common and serious pulmonary complications in SCA. It is characterized by the sudden onset of chest pain, fever, and respiratory distress, often accompanied by pulmonary infiltrates on imaging studies. ACS is typically triggered by vaso-occlusion within the pulmonary vasculature, leading to ischemia, inflammation, and ultimately, pulmonary infarction. Prompt recognition and aggressive management of ACS are paramount, as delayed intervention can result in respiratory failure and death.[20-21]

Pulmonary hypertension (PH) represents a progressive and debilitating complication of SCA, significantly impacting quality of life and survival.[22] Chronic hemolysis, endothelial dysfunction, and thrombotic events contribute to the development of PH in SCA patients. Pulmonary arterial hypertension (PAH), characterized by elevated pulmonary vascular resistance and right heart strain, is a particularly devastating subtype of PH in SCA. PAH is associated with a high risk of morbidity and mortality, necessitating early detection and targeted therapeutic interventions to mitigate disease progression. In addition to ACS and PH, SCA patients are predisposed to other respiratory conditions that further exacerbate pulmonary morbidity.[23] Asthma is more prevalent in individuals with SCA compared to the general population, likely due to airway inflammation, bronchial hyperresponsiveness, and environmental factors. Obstructive sleep apnea (OSA) is also common in SCA, characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, leading to disrupted sleep patterns and daytime fatigue. Furthermore, restrictive lung disease, characterized by decreased lung compliance and impaired gas exchange, can occur as a consequence of chronic inflammation, fibrosis, and pulmonary vascular remodeling in SCA.

Academic Perspectives and Research Advancements

Academic perspectives and research advancements in the realm of sickle cell anemia (SCA) and its pulmonary complications have significantly enriched our understanding of the underlying pathophysiological mechanisms and informed therapeutic strategies. Over the years, a plethora of studies conducted by researchers worldwide have shed light on various facets of this complex interplay, paving the way for targeted interventions and improved clinical outcomes.One of the key areas of focus in academic research has been unraveling the molecular mechanisms underlying pulmonary complications in SCA.[24-25] Chronic hemolysis, a hallmark feature of SCA, has emerged as a central player in the pathogenesis of pulmonary hypertension (PH). Studies have elucidated how the release of free hemoglobin and heme, coupled with endothelial dysfunction and oxidative stress, contribute to pulmonary vascular remodeling and vasoconstriction. This understanding has paved the way for the development of novel therapeutic agents targeting specific pathways involved in the pathogenesis of PH, such as endothelin receptor antagonists and nitric oxide donors.

Furthermore, advancements in genetic research have provided invaluable insights into the heterogeneity of SCA and its pulmonary complications. Genome-wide association studies (GWAS) have identified genetic modifiers that influence the severity and clinical course of SCA, including genes involved in pulmonary function, inflammation, and vascular homeostasis.[26] These findings have not only deepened our understanding of the underlying genetic architecture of SCA but also hold promise for personalized medicine approaches, wherein genetic profiling could inform treatment decisions and risk stratification for pulmonary complications.In addition to elucidating the pathophysiological mechanisms, academic research has also focused on evaluating the efficacy and safety of therapeutic interventions for SCA-related pulmonary complications.[27] Clinical trials assessing the use of hydroxyurea, a disease-modifying agent, have demonstrated its ability to reduce vaso-occlusive events and ameliorate pulmonary hypertension in SCA patients. Similarly, studies evaluating the role of transfusion therapy, pulmonary vasodilators, and targeted therapies have provided valuable insights

into their efficacy in improving pulmonary function and clinical outcomes. Moreover, academic collaborations and multicenter research initiatives have facilitated the pooling of resources and expertise, accelerating the pace of discovery in the field of SCA and pulmonary complications. Collaborative consortia, such as the Sickle Cell Disease Clinical Research Network (SCDCRN) and the Pulmonary Hypertension and Sickle Cell Disease Consortium (PHSCC), have enabled the conduct of large-scale studies and longitudinal cohorts, providing robust data to guide clinical practice and inform future research directions.

Therapeutic Strategies

Therapeutic strategies for managing pulmonary complications in sickle cell anemia (SCA) encompass a multidisciplinary approach aimed at alleviating symptoms, preventing disease progression, and improving overall quality of life for affected individuals. These strategies span pharmacological interventions, supportive care measures, and, in some cases, interventional procedures.

1. Disease-Modifying Therapy: Hydroxyurea stands as a cornerstone in the management of SCA, exerting its effects by increasing fetal hemoglobin levels, reducing vaso-occlusive events, and ameliorating pulmonary hypertension. Its use has been associated with decreased frequency of acute chest syndrome (ACS) episodes, improved exercise tolerance, and reduced hospitalizations in SCA patients.[29-30] Furthermore, ongoing research is exploring the potential benefits of emerging disease-modifying agents, such as voxelotor and crizanlizumab, in mitigating pulmonary complications and improving clinical outcomes.

2. Transfusion Therapy: Red blood cell transfusions play a crucial role in the management of acute and chronic complications in SCA, particularly in the prevention and treatment of ACS.[30-31] Exchange transfusion, wherein a patient's blood is replaced with donor blood, helps reduce the proportion of sickled red blood cells, alleviate hypoxemia, and mitigate pulmonary vascular occlusion. Additionally, chronic transfusion therapy may be indicated in select cases to prevent recurrent strokes and ameliorate pulmonary hypertension.

3. Pulmonary Vasodilators: Pulmonary hypertension (PH) represents a significant and challenging complication of SCA, necessitating targeted therapeutic interventions to alleviate symptoms and improve outcomes. Pulmonary vasodilators, including prostacyclin analogs (e.g., epoprostenol, treprostinil) and phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), have shown promise in reducing pulmonary vascular resistance, improving exercise capacity, and enhancing quality of life in SCA patients with PH. Combination therapy with multiple vasodilators may be considered in refractory cases to achieve optimal hemodynamic outcomes.

4. Supportive Care Measures: Comprehensive supportive care measures are integral to the management of pulmonary complications in SCA, encompassing vaccinations, nutritional support, and pulmonary rehabilitation. Vaccinations against encapsulated bacteria, such as Streptococcus pneumoniae and Haemophilus influenzae type b, help reduce the risk of infections, including pneumonia, in SCA patients. Nutritional support, including supplementation with folic acid and vitamin D, aims to optimize hematopoiesis and bone health. Pulmonary rehabilitation programs, incorporating exercise training, breathing exercises, and education, can improve pulmonary function, exercise tolerance, and quality of life in SCA patients with respiratory symptoms.

5. Interventional Procedures: In select cases of severe pulmonary hypertension or ACS refractory to medical therapy, interventional procedures such as pulmonary artery catheterization, balloon pulmonary angioplasty, or lung transplantation may be considered. These procedures are reserved for patients with advanced disease and are typically performed in specialized centers with expertise in the management of pulmonary complications in SCA.

Challenges and Future Directions

Challenges and future directions in the management of pulmonary complications in sickle cell anemia (SCA) underscore the need for continued research, innovative strategies, and comprehensive approaches to improve outcomes and quality of life for affected individuals. Despite significant advancements in our understanding and management of SCA-related pulmonary complications, several challenges persist, necessitating concerted efforts to address them effectively.

1. Healthcare Disparities: Disparities in healthcare access and delivery remain a significant challenge in the management of SCA-related pulmonary complications, particularly among underserved and marginalized populations.[32] Limited access to specialized care, socioeconomic barriers, and geographic disparities contribute to delayed diagnosis, suboptimal treatment, and poorer outcomes. Addressing healthcare disparities requires multifaceted approaches, including community outreach initiatives, patient education programs, and policy interventions aimed at improving access to comprehensive care and reducing healthcare inequities.

2. Limited Therapeutic Options: Despite recent advancements in targeted therapies and disease-modifying agents, the therapeutic armamentarium for SCA-related pulmonary complications remains limited.[33] Existing treatments often target downstream manifestations of the disease and may not address the underlying pathophysiological mechanisms comprehensively. Future research efforts should focus on identifying novel therapeutic targets, developing innovative treatment modalities, and conducting rigorous clinical trials to evaluate the efficacy and safety of emerging therapies in SCA patients with pulmonary complications.

3. Disease Heterogeneity: SCA is a genetically and clinically heterogeneous disorder, with considerable variability in disease severity, clinical manifestations, and treatment responses among affected individuals. This heterogeneity challenges in patient management, risk stratification, and treatment optimization, necessitating personalized medicine approaches tailored to individual patient characteristics, including genetic modifiers, clinical phenotypes, and environmental factors. Integrating genomic data, biomarkers, and clinical parameters into predictive models can facilitate precision medicine approaches and optimize therapeutic decision-making in SCA-related pulmonary complications.[34-36]

4. Long-term Monitoring and Surveillance: Longitudinal monitoring and surveillance of SCA patients with pulmonary complications are essential to detect disease progression, assess treatment responses, and prevent complications. However, existing surveillance systems may be fragmented, leading to gaps in follow-up care and suboptimal outcomes. Implementing comprehensive surveillance programs, leveraging electronic health records, telemedicine platforms, and patient registries, can facilitate proactive monitoring, early intervention, and continuity of care for SCA patients with pulmonary complications.

5. Research Gaps and Knowledge Gaps: Despite significant progress in the field, several research gaps and knowledge gaps persist, hindering our understanding of the pathophysiology, natural history, and optimal management of SCA-related pulmonary complications. Key areas for future research include elucidating the genetic determinants of pulmonary complications, identifying novel biomarkers for risk stratification and disease monitoring, and conducting prospective studies to evaluate the long-term efficacy and safety of emerging therapies. Collaborative research initiatives, interdisciplinary collaborations, and funding support are essential to address these gaps and drive innovation in SCA research.

Conclusion

Sickle cell anemia (SCA) poses significant challenges due to its intricate interplay with pulmonary complications, necessitating a multifaceted approach to management. Through

this review, we have explored the academic perspectives, research advancements, therapeutic strategies, challenges, and future directions in addressing SCA-related pulmonary complications. Academic research has deepened our understanding of the pathophysiological mechanisms underlying pulmonary complications in SCA, elucidating the roles of chronic hemolysis, endothelial dysfunction, and genetic modifiers. These insights have informed the development of targeted therapeutic interventions aimed at mitigating pulmonary hypertension, reducing vaso-occlusive events, and improving clinical outcomes. Therapeutic strategies for managing pulmonary complications in SCA encompass a comprehensive approach, including disease-modifying therapy, transfusion therapy, pulmonary vasodilators, supportive care measures, and, in select cases, interventional procedures. However, challenges such as healthcare disparities, limited therapeutic options, disease heterogeneity, and research gaps persist, highlighting the need for continued collaboration, innovation, and advocacy efforts.

References

1. Ilesanmi OO. Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy. Hematology reports. 2010;2(1): e2.
2. Alaka AA, Alaka OO, Iyanda AA. Nitric oxide and zinc levels in sickle cell hemoglobinopathies: a relationship with the markers of disease severity. Pomeranian Journal of Life Sciences. 2023;69(1):6-12.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023;102(48): e36462.
6. Bajpai N, Acharya S, Ahuja A, Saboo K, BATRA N. Guarding Health: A Comprehensive Review of Nosocomial Infections in Sickle Cell Anemia, a Multifaceted Approach to Prevention. Cureus. 2024;16(1).
7. Rajput HS, Kumari M, Talele C, Sajan C, Saggu V, Hadia R. Comprehensive Overview of Sickle Cell Disease: Global Impact, Management Strategies, And Future Directions. Journal of Advanced Zoology. 2024;45(1).
8. Elendu C, Amaechi DC, Elendu TC, Ibhiedu JO, Torubiri AO, Okoye OK. Comprehensive review of aortic aneurysms, dissections, and cardiovascular complications in connective tissue disorders. Medicine. 2023;102(48): e36499.
9. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology. 2024;2(3):81-95.
10. Haider HK, Ashraf M. Preconditioning and stem cell survival. Journal of cardiovascular translational research. 2010; 3:89-102.
11. Sun Z, Yun Z, Lin J, Sun X, Wang Q, Duan J, Li C, Zhang X, Xu S, Wang Z, Xiong X. Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction. Journal of Translational Medicine. 2024;22(1):404.
12. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
13. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
14. Writing Committee Members, Isselbacher EM, Preventza O, Hamilton Black III J, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice

Guidelines. Journal of the American College of Cardiology. 2022;80(24): e223-393.
15. Writing Group Members, Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey Jr DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, American association for thoracic surgery, American college of radiology, American stroke association, society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, society of interventional radiology, society of .... Circulation. 2010;121(13): e266-369.
16. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023;6(4):12-17.
17. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
18. Lawless CE, Asplund C, Asif IM, Courson R, Emery MS, Fuisz A, Kovacs RJ, Lawrence SM, Levine BD, Link MS, Martinez MW. Protecting the heart of the American athlete: proceedings of the American College of Cardiology sports and exercise cardiology think tank October 18, 2012, Washington, DC. Journal of the American College of Cardiology. 2014;64(20):2146-2171.
19. Ballas SK. Sickle cell disease: Classification of clinical complications and approaches to preventive and therapeutic management. Clinical hemorheology and microcirculation. 2018;68(2-3):105-128.
20. Yusuf BJ, Abba AA, Tasiu M. Acute chest syndrome. Sub-Saharan African Journal of Medicine. 2014;1(3):111-118.
21. Helvaci M, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Acute chest syndrome and pulmonary hypertension in sickle cell diseases. World Family. 2022.
22. Delino S, Tasada M, Argiri V. Combination of exchange transfusion treatment and hydroxyurea cause beneficial changes to laboratory parameters and clinical outcome in patients with sickle cell disease/beta thalassemia compared with hydroxyurea or exchange transfusion alone. Hematology & Transfusion International Journal. 2016;2(4):6.
23. Jain S, Bakshi N, Krishnamurti L. Acute chest syndrome in children with sickle cell disease. Pediatric allergy, immunology, and pulmonology. 2017;30(4):191-201.
24. Serrano AL, Mann CJ, Vidal B, Ardite E, Perdiguero E, Muñoz-Cánoves P. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Current topics in developmental biology. 2011; 96:167-201.
25. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2): e36898.
26. Hirschhorn JN, Gajdos ZK. Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Annual review of medicine. 2011; 62:11-24.
27. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018; 19:113-147.
28. Ballas SK. The evolving pharmacotherapeutic landscape for the treatment of sickle cell disease. Mediterranean Journal of Hematology and Infectious Diseases. 2020;12(1).
29. Obeagu EI, Obeagu GU. Reactive Oxygen Species and Antioxidant Defense Mechanisms in Sickle Cell Anemia: A Review. Elite Journal of Laboratory Medicine. 2024;2(3):1-0.
30. Ozment CP, Turi JL. Iron overload following red blood cell transfusion and its impact on disease severity. Biochimica et Biophysica Acta (BBA)-General Subjects. 2009 ;1790(7):694-701.
31. Tzounakas VL, Valsami SI, Kriebardis AG, Papassideri IS, Seghatchian J, Antonelou MH. Red cell transfusion in paediatric patients with thalassaemia and sickle cell disease: current

status, challenges and perspectives. Transfusion and apheresis science. 2018;57(3):347-357.
32. Ogunyemi O. *Premarital Testing, Informed Consent and Decision Making Towards Prevention of Sickle Cell Disease: Behavior of Intending Couples and Religious Institutions in Ogbomoso Metropolis* (Master's thesis, Center for Bioethics and Research). 2023
33. Karkoska KA, Gollamudi J, Hyacinth HI. Molecular and environmental contributors to neurological complications in sickle cell disease. Experimental Biology and Medicine. 2023;248(15):1319-1332.
34. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
35. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
36. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.

Access this Article in Online	
	Website: www.ijcrims.com
Quick Response Code	Subject: Medical Sciences
DOI: 10.22192/ijcrms.2024.10.04.005	

How to cite this article:
Emmanuel Ifeanyi Obeagu and Muhammad Tukur. (2024). Sickle Cell Anemia and Pulmonary Complications: Academic Perspectives and Therapeutic Strategies. Int. J. Curr. Res. Med. Sci. 10(4): 46-53.
DOI: http://dx.doi.org/10.22192/ijcrms.2024.10.04.005